115
Participants
Start Date
October 21, 2019
Primary Completion Date
October 30, 2026
Study Completion Date
October 30, 2026
GAd-209-FSP low dose
GAd20-209-FSP IP, low dose
MVA-209-FSP low dose
MVA-209-FSP IP, low dose
GAd-209-FSP high dose
GAd20-209-FSP IP, high dose
MVA-209-FSP high dose
MVA-209-FSP IP, high dose
GAd20-209-FSP, RP2D
GAd20-209-FSP IP, RP2D
MVA-209-FSP, RP2D
MVA-209-FSP IP, RP2D
KEYTRUDA®
anti-PD-1 checkpoint inhibitor (200 mg; Q3W)
Cliniques Universitaires Saint-Luc - Centre du Cancer, Brussels
CHU de Liège, Liège
Centre Hospitalier de l'Ardenne - Libramont - Clinique du Sein, Libramont
NYU Langone Medical Center, New York
Weill Cornell Medicine / New York-Presbyterian Hospital, New York
Candiolo cancer Center,FPO IRCCS, Candiolo
Hospital Universitario Reina Sofia, Córdoba
Roswell Park Comprehensive Cancer Center, Buffalo
Hospital Universitario de A Coruna, A Coruña
Hospital Clínico Universitario de Santiago de Compostela, Santiago de Compostela
Hospital Universitario Virgen de las Nieves, Granada
IRCCS Ospedale San Raffaele, Milan
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan
Ospedale Niguarda, Milan
Johns Hopkins University, Baltimore
Hospital General Universitario Gregorio Marañón, Madrid
Clinica Universidad de Navarra, Madrid
Hospital Universitario Fundación Jiménez Díaz, Madrid
Hospital Universitario 12 de Octubre, Madrid
Hospital Universitario La Paz, Madrid
Clinica Universidad de Navarra, Pamplona
Mt. Sinai, Miami Beach
Boca Raton Clinical Research, Plantation
Complejo Asistencial de Salamanca, Salamanca
Hospital General Universitario de Valencia, Valencia
Goshen Center for Cancer Care, Goshen
Hospital Universitario Miguel Servet, Zaragoza
AOUS Policlinico Le Scotte, Siena
Washington University School of Medicine, Division of Oncology, St Louis
MD Anderson Cancer Center (MDACC), Houston
Aorn Sg Moscati, Avellino
USC Norris Comprehensive Cancer Center, Los Angeles
City of Hope Comprehensive Cancer Center, Duarte
City of Hope Comprehensive Cancer Center, Irvine
USC Norris Comprehensive Cancer Center, Newport Beach
Mount Sinai Hospital, Toronto
Princess Margaret Cancer Center, Toronto
Hospital Del Mar, Barcelona
Hospital Universitari Dexeus, Barcelona
Hospital Vall d'Hebron, Barcelona
Institut Catala d'Oncologia Hospitalet, Barcelona
Hospital Clinic de Barcelona, Barcelona
Hospital Universitario HM Sanchinarro, Madrid
Hospital Universitario Marques de Valdecilla, Santander
University Clinical Hospital Valencia, Valencia
University College London Hospitals NHS Foundation Trust Cancer Clinical Trials Unit, London
Lead Sponsor
Merck Sharp & Dohme LLC
INDUSTRY
Nouscom SRL
INDUSTRY